Black Diamond Therapeutics Inc(BDTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:28 PM ET (Korea 10/31 08:28)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.74 | Insider Own | 19.67% | Shs Outstand | 57.5M | Perf Week | -5.32% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | -54.56% | Insider Trans | - | Shs Float | 46.1M | Perf Month | -5.32% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.09 | Inst Own | 54.54% | Short Float | 10.84% | Perf Quarter | 2.59% |
| Income | -0.04B | P/S | - | EPS this Y | -258.01% | Inst Trans | -5.81% | Short Ratio | 7.32 | Perf Half Y | -31.54% |
| Sales | 0.00B | P/B | 1.06 | EPS next 5Y | - | ROA | -29.21% | Short Interest | 5.00M | Perf YTD | -26.75% |
| Book/sh | 1.67 | P/C | 0.93 | EPS past 3/5Y | - | ROE | -37.21% | 52W High | -63.97% ($4.94) | Perf Year | -53.4% |
| Cash/sh | 1.92 | P/FCF | - | Sales past 3/5Y | - | ROIC | -38.97% | 52W Low | 11.25% ($1.60) | Perf 3Y | -1.66% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -392.92% | Gross Margin | - | Volatility(W/M) | 8.86% 7.19% | Perf 5Y | -76.76% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.28 | EPS Q/Q | 7.1% | Profit Margin | - | RSI (14) | 45.38 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.28 | Sales Q/Q | - | SMA20 | -2.86% ($1.83) | Beta | 3.48 | Target Price | $10 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/8/5 | SMA50 | -8.67% ($1.95) | Rel Volume | 0.76 | Prev Close | $1.86 |
| Employees | 21 | LT Debt/Eq | 0.14 | EPS/Sales Surpr. | 13% - | SMA200 | -18.78% ($2.19) | Avg Volume(3M) | 0.68M | Price | $1.78 |
| IPO | 2020/1/30 | Option/Short | Yes/Yes | Trades | 2518 | Volume | 520,160 | Change | -4.3% |
🧬 Black Diamond Therapeutics (BDTX) is a U.S. clinical-stage biotech company focused on precision oncology. It aims to develop targeted cancer therapies that address specific collections of oncogenic mutations all at once, advancing treatment candidates in solid tumor areas such as lung cancer through clinical stages via a pipeline leveraging brain-penetrant small-molecule compounds.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded less than usual. That is 76% of its average volume.
BDTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -258.0% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -76.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 54.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #354 of 597 in the industry
Based on market cap of $102M.
UNCY#350 Unicycive Therapeutics Inc $104M PER - 
TLSA#351 Tiziana Life Sciences Ltd $103M PER - 
ENGN#352 enGene Therapeutics Inc $103M PER - 
IMUX#353 Immunic Inc $102M PER - BDTX#354 Black Diamond Therapeutics Inc $102M PER - 
FAQ
What kind of company is BDTX?
BDTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BDTX?
The market cap of BDTX is approximately $102M, ranking 4,448 within its sector.
What is the 52-week high and low for BDTX?
BDTX has recorded a 52-week high of $4.94 and a low of $1.60.
